> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# State Street Holds 4% Of Corvus As The Drug Developer's Trial Bill Grows
- URL: https://www.bullished.co/state-street-holds-4-of-corvus-as-the-drug-developers-trial-bill-grows-6f32f0e5/
- Published: 2026-11-10T12:16:32.000Z
- Updated: 2026-11-10T12:16:32.000Z
- Description: Corvus expects its cash to last into the second quarter of 2028, with a lymphoma-study assessment expected in early 2027.
- Author: Matteo Parrino
- Tags: SEC Filings, CRVS, Industry: Healthcare

State Street reported a [4% stake](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000636/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) in [Corvus Pharmaceuticals](https://www.bullished.co/tag/crvs/), which develops experimental treatments for immune diseases and cancer, in a passive ownership disclosure filed Tuesday. The position covered 3,331,535 shares as of September 30, 2026, while Corvus's third-quarter research bill rose to $17.8 million from $8.5 million a year earlier.

## A Passive Position, Not A Control Bid

State Street said it held the investment for ordinary business purposes, rather than to change or influence Corvus's control. The 4% figure measures its beneficial ownership of the common-stock class.

State Street had [shared voting power](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000636/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) over 3,233,973 shares and no sole voting power. It also reported shared power to dispose of 3,331,535 shares. Those holdings describe the September 30 position, not an investment made on Tuesday.

Corvus's market value was $957 million as of 7:12 a.m. ET Tuesday.

## Trials Drive A Larger Research Bill

Corvus Chief Financial Officer Leiv Lea put third-quarter [research spending](https://seekingalpha.com/news/4668463-corvus-anticipates-ptcl-futility-analysis-in-q1-2027-while-guiding-cash-runway-into-q2-2028?ref=bullished.co) at $17.8 million, versus $8.5 million a year earlier. The company attributed the increase to personnel and trial costs across its work in lymphoma, atopic dermatitis, hidradenitis suppurativa and asthma.

Its quarterly [net loss](https://finance.yahoo.com/healthcare/articles/corvus-pharmaceuticals-inc-crvs-q3-151541590.html?ref=bullished.co) widened to $20.3 million from $10.2 million a year earlier. Corvus had $202.9 million in cash at September 30 and expects that money to fund operations into the second quarter of 2028, beyond its expected late-stage lymphoma results.

The company's lead drug candidate, soquelitinib, is being tested in a late-stage trial for relapsed peripheral T cell lymphoma. It also began a mid-stage atopic dermatitis trial in March 2026\. Corvus's other candidates, ciforadenant and mupadolimab, target solid tumors.

Corvus has no drugs approved for sale. It relies on outside contract manufacturers rather than owning manufacturing facilities, and its development work targets proteins involved in immune-cell maturation and function.

Corvus expects a [first-quarter 2027 assessment](https://finance.yahoo.com/healthcare/articles/corvus-pharmaceuticals-inc-crvs-q3-151541590.html?ref=bullished.co) of its late-stage lymphoma trial to determine whether the study should continue or stop because it is unlikely to succeed.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — STATE STREET CORPORATION re: CORVUS PHARMACEUTICALS INC (CRVS)](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000636/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [Corvus Pharmaceuticals Inc (CRVS) Q3 2026 Earnings Call Highlights: Strong Cash Runway and Key ...](https://finance.yahoo.com/healthcare/articles/corvus-pharmaceuticals-inc-crvs-q3-151541590.html?ref=bullished.co) — Yahoo Finance
- [Corvus anticipates PTCL futility analysis in Q1 2027 while guiding cash runway into Q2 2028 (NASDAQ:CRVS) | Seeking Alpha](https://seekingalpha.com/news/4668463-corvus-anticipates-ptcl-futility-analysis-in-q1-2027-while-guiding-cash-runway-into-q2-2028?ref=bullished.co) — seekingalpha.com
- [Corvus Pharmaceuticals to Present at the 2026 Jefferies](https://www.globenewswire.com/news-release/2026/11/09/3398933/0/en/corvus-pharmaceuticals-to-present-at-the-2026-jefferies-global-healthcare-conference-in-london.html?ref=bullished.co) — globenewswire.com

### More on Corvus Pharmaceuticals

- [Corvus Stock Soars 8.22% — Adding $67 Million Even With Eczema Results Delayed](https://www.bullished.co/corvus-stock-soars-8-22-adding-67-million-even-with-eczema-results-delayed-98414bcd/)
- [Corvus Spends $17.8 Million On Research As Soquelitinib Trials Expand Across Immune Diseases](https://www.bullished.co/corvus-spends-17-8-million-on-research-as-soquelitinib-trials-expand-across-immune-d2e065ee/)
- [Corvus Sets March 2027 For Angel's Atopic Dermatitis Data, Citing A Blinding Window](https://www.bullished.co/corvus-sets-march-2027-for-angels-atopic-dermatitis-data-citing-a-blinding-window-f2c0c33f/)

[All Corvus Pharmaceuticals (CRVS) coverage →](https://www.bullished.co/tag/crvs/)